The San Francisco-based biopharmaceutical company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options.
"We are bullish on Xtandi in pre-metastatic prostate cancer and triple negative breast cancer," the firm said in an analyst note. "We see Xtandi expansion into broader breast cancer as well as immuno-therapeutic indications."
Xtandi is a prostate cancer drug the company jointly developed with Astellas Pharma.
Credit Suisse anticipates that the drug will initiate a host of clinical trials that will demonstrate its utility as an immune-oncology combination asset.
Shares of Medivation are declining by 1.96% to $37.17 at the start of trading on Thursday.
Separately, TheStreet Ratings Team has a "hold" rating with a score of C+ on Medivation.
The primary factors that have impacted the rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks.
The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, the team finds that the stock has had a generally disappointing performance in the past year.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: MDVNMDVN data by YCharts